N-terminal propeptide of type I11 procollagen (PIIINP) concentration was measured in cord serum, amniotic fluid, and maternal serum from high-risk pregnancies. The fetal PIIINP variability was shown to be independent of the maternal serum PIIINP values. Although a highly significant negative correlation was found between the fetal propeptide level and gestational age in both appropriate-for-gestationalage neonates (n = 504) and small-for-gestational-age infants (n = 98), the PIIINP concentration in cord serum or amniotic fluid of small-for-gestational-age infants was significantly lower compared with that of appropriate-for-gestational-age infants matched for postconceptional age. PIIINP assay may thus serve as a dynamic biochemical indicator of deviant fetal growth. The PIIINP results were also related to the severity or duration of intrauterine growth retardation, as indicated by significantly lower propeptide cord serum values in nonmalfonned small-for-gestational-age infants with small head circumference, known as an index for the chronicity of fetal nutritional deprivation. Preeclampsia, maternal diabetes or smoking, and congenital anomalies appeared not to be associated with any alteration of fetal propeptide concentration, provided they did not cause fetal growth deceleration. The finding of extremely high cord serum PIIINP IUGR rates among the most pressing problems in perinatology (1). .To this end, there remains a need for objective measurement of fetal growth itself, independent of ultrasonographic in utero observation. During childhood, the serum concentration of PIIINP closely mirrors the shape of the growth velocity curve, but n o significant correlation with either height o r body weight values in six newborn infants with the Potter malformation sequence led to the speculation that large amounts of propeptides or their fragments usually are excreted by the fetal kidneys into the amniotic fluid. We suggest that determination of the PIIINP level in amniotic fluid or cord serum, obtained by amniocentesis and percutaneous umbilical sampling, may be a helpful adjunctive biochemical parameter in future research protocols assessing fetuses at risk for intrauterine growth retardation. (Pediufr Res 36: [71][72][73][74][75][76] 1994) Abbreviations PIIINP, N-terminal propeptide of type 111 procollagen ABB, antibody-based RIA for PIIINP recognizing predominantly the intact propeptide (Col 1-3) FAB, RIA for PIIINP using Fab' antibody fragments that are equally reactive with Col 1-3 and Col 1 fragments SGA, small for gestational age AGA, appropriate for gestational age PI, ponderal index OFC, occipitofrontal circumference r,, Spearman rank correlation coefficient SD score, standard deviation score IUGR, intrauterine growth retardation w a s found in the normal childhood population (2-5). O u r study o n PIIINP in the late gestation fetus showed identical relations t o fetal somatic growth rate of A G A infants during the second half of pregnancy (6). However, in the childhood studies, the PIIINP serum levels were significantly lower for age-matched patients with various growth disorders (e.g. growth h o r m o n e deficiency, Turner syndrome) (2-5). These observations prompted the hypothesis that assay of PIIINP concentration in cord serum o r amniotic fluid of newborn infants may also b e a method for quantitative assessment of deviant fetal growth in high-risk pregnancies and may allow u s t o determine the importance of the alleged phenomenon of
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ysis of high-risk pregnancies. The aim of the present study was to assess the clinical Statistical methods. Correlations between PIIINP levels usefulness of the PIIINP assay in cord serum and amni-and auxanologic data were evaluated by Spearman rank otic fluid for the detection of deviant fetal growth during correlation analysis (8). A multivariate regression analythe second half of high-risk pregnancies.
sis was used to define those variables exerting influence independent of others. The Mann-Whitney U test was used for comparing prognostic groups. METHODS RESULTS Subjects. SGA infants form part of the computer database file of 602 neonatal records also used for the study of AGA infants (6). Ninety-eight of the 602 newborns were classified as SGA infants because their birth weight was below the 10th percentile (matched for sex and parity) according to the Dutch data on intrauterine growth (7). Among these SGA infants, 62.2% (n = 61) were born after a pregnancy of less than 37 completed weeks. Cord serum was assayed in all SGA infants, and in 35 of them the PIIINP test could also be performed on paired amniotic fluid specimens.
Thirty-four newborns were the offspring of 29 (of 535) pregnancies complicated by preeclampsia, defined as systemic hypertension aftef the 20th wk of pregnancy (systolic or diastolic blood pressure r 140 or 90 mm Hg, respectively) with proteinuria (~0 . 3 gIL), edema, or both. There were 12 single births from mothers with insulin-dependent diabetes, and 156 (29%) of the 535 mothers were smokers during pregnancy, 46 of them "heavy" smokers (more than 20 cigarettes a day).
During the study, six infants with the Potter malformation sequence were studied for PIIINP cord serum levels. Three of them had bilateral renal cystic dysplasia, two had bilateral renal agenesis, and one had infantile polycystic kidney disease. All these infants died within 24 h because of fetal anuria and anhydramnios-related lung hypoplasia.
The PIIINP concentration was also determined in the serum of 58 mothers from our study group.
This study received the approval of the ethical committee at the University Hospital Gent. Informed consent was obtained from the parents before they participated in the study.
Sampling and storage procedures were identical with those described in our previous PIIINP study on healthy AGA infants (6).
Biochemical methods. Two different assay methods (regular PIIINP assay, i.e. RIAgnost P-111-P, and Fabmodified PIIINP assay; Behringwerke AG, Marburg, Germany) were used for the quantification of the PIIINP concentrations in cord serum and amniotic fluid. The crossover interrelationship between FAB and ABB assays for PIIINP concentrations in both fetal biologic fluids was studied on the whole cohort of infants, and their interchangeability for clinical research on fetal growth rate was demonstrated in our former report (6). Therefore, only the largest number of identical test results available, FAB assay of cord serum and ABB assay Cord serum PIIINP levels (FAB assay). Mere visual inspection of a simple x-y plot of PIIINP serum level (y) on birth weight (x) shows an obvious difference of the relation between the serum PIIINP level of SGA infants (n = 98) and birth weight compared with that for AGA infants (n = 504) (Fig. 1) . Upon comparison of the data in AGA infants with those in SGA infants matched for fetal lifetime, highly significant differences (p < 0.0001) in serum PIIINP were found, although even in the SGA group a significant negative correlation (p < 0.0001) between PIIINP concentration and gestational age remained (covariance analysis) ( Table 1) There was also no statistical difference (p = 0.12) between the PIIINP levels in two groups of SGA infants matched for gestational age but differing only by single (n = 47) or multiple birth (n = 24) circumstances. The individual PIIINP serum levels (FAB assay) of all SGA infants (n = 98) are plotted on the "standard" (6) percentile chart (Fig. 3) . Thirty (88%) of 34 offspring of preeclamptic mothers were born prematurely. Twenty-two of the 34 newborns were SGA. Covariance analysis of PIIINP values with gestational age revealed that only IUGR and not preeclampsia was related to the PIIINP variability (p = 0.94, F ratio = 0.007).
None of the newborns (n = 12) from mothers with diabetes were growth retarded and none had congenital anomalies. Their mean PIIINP serum level was not sig-PI (birth weightibirth length3 x 100) is frequently used for rough differentiation of chronic (or symmetric) and subacute (or asymmetric) IUGR (1, 9, 10). When covariation with gestational age was taken into account, the significant (p < 0.0001) correlation coefficient between PIIINP level and PI in AGA as well as in SGA infants was no longer statistically meaningful, even after exclusion of the infants with structural anomalies. 
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nificantly (p = 0.66) different from the level in agematched (3340 wk) AGA infants (n = 336). The cord serum PIIINP level in relation to smoking revealed no significant differences between infants of nonsmokers, moderate smokers, and heavy smokers matched for gestational age (Kruskall-Wallis analysis). However, PIIINP value in the serum of infants of heavysmoking mothers was significantly @ < 0.001) lower in their SGA offspring compared with that in age-matched AGA infants.
Although two of the six neonates with the Potter malformation sequence were also growth retarded, the PIIINP cord serum level in all was extremely high and well outside the normal range for the respective gestational ages (Fig. 3) . Three of the six patients with Potter sequence belonged to multiple birth pregnancies. The PIIINP level in cord blood of the second healthy twin was within the normal range for gestational age.
Amnioticfluid PZZZNP levels (ABB assay). A simple x-y plot of amniotic fluid PIIINP level (y) on birth weight (x) illustrates that the amniotic fluid propeptide level probed by the ABB assay in SGA infants (n = 35) is apparently different from that in AGA infants (n = 268) (Fig. 4) . .*
When the data of SGA infants were compared with those in AGA infants matched for postconceptional lifetime, significant differences in amniotic fluid PIIINP level were found for full-term (37-40 wk: p < 0.05) as well as for preterm infants (33-36 wk: p < 0.0001). However, covariance analysis for amniotic fluid PIIINP concentration with gestational age was still significant in SGA infants @ c 0.001).
The relationship of the amniotic fluid PIIINP level to birth weight, expressed as SD score, showed no significant correlation for the total group of infants (n = 303; r, = -0.0002, p = 0.99). A significant, albeit weak, correlation with the SD score was found for PIIINP level of neonates with an SD score less than -2 (n = 25; r, = 0 . 4 1 ,~ < 0.05). The PI of age-matched SGA infants did not correlate with the amniotic fluid propeptide value.
The individual ABB assay PIIINP levels in amniotic fluid of all SGA infants (n = 35) are plotted on the "standard" (6) percentile chart (Fig. 5) .
Maternal serum PZZZNP levels (FAB assay). PIIINP serum levels (FAB assay) were measured in 58 maternal blood specimens collected during labor or immediately after delivery. The serum PIIINP concentrations from mothers (n = 28) of uncomplicated, single, term pregnancies were significantly higher (mean k SD: 127. ing birth between the 25th and 37th wk of pregnancy (mean + SD: 71.2 -t 6.1 pg/L). PIIINP levels in the serum of either mothers with twin pregnancies (n = 10) or mothers suffering from preeclampsia (n = 3) (mean -t SD: 157.9 + 14.2 pg/L) were significantly higher @ < 0.001) than the ones in mothers with age-matched subsequent uncomplicated singleton preterm-birth pregnancies.
DISCUSSION
In our previous study (6), it was shown that PIIINP level in cord serum and amniotic fluid of AGA fetuses is directly correlated with age-related fetal somatic growth rate during the second half of pregnancy. The results presented here show in addition that cord serum or amniotic fluid PIIINP concentration assay enables the investigator to discern deviant from normal fetal growth, inasmuch a s SGA fetuses have significantly lower propeptide values in comparison with age-matched AGA infants. This is of paramount importance, because this biochemical approach to the evaluation of fetal growth may have the singular advantage of discovering growth rate decelerations at one point in time and predicting a probable outcome, whereas conventional auxologic methods such as ultrasound anthropometry can only reveal the point in physical growth already reached at the time of observation. Calculation from such anthropometric growth rates are necessarily retrospective in nature (13) . To what extent propeptide levels in cord serum or amniotic fluid may be prompt measures of a change in fetal growth activity, well before clinical or ultrasonographic changes become apparent, must still be investigated by more detailed prospective studies of individual pregnancies at high risk for subsequent IUGR. The study of the correlation of PIIINP levels with Doppler flow resistance indices of fetal cerebral vessels-shown to reach adequate accuracy in predicting IUGR in high-risk fetuses (14,15)--deserves priority, inasmuch as it may be of great value in the early identification of IUGR before irreversible fetal brain damage has occurred.
Our results are at variance with the findings reported by Yunoki et al. (16) , who found no difference of PIIINP quantities in cord serum between AGA and SGA neonates matched for postconceptional age. This inconsistency may be explained by the fact that in the Yunoki study interferences by either maternal or fetal auxanologic data or complications of pregnancy and labor were not taken into account, and SGA infants with fetal malformations or those born to hypertensive mothers were excluded. Moreover, the majority of the SGA infants (n = 22) in that study were near-or full-term neonates. At the end of pregnancy, as demonstrated by the results presented (Fig. 3) and as also assumed by Yunoki et al. (16) , systemic collagen synthesis must stabilize in SGA as well as in AGA fetuses.
The degree of IUGR cannot be quantitatively assessed relating PI to serum propeptide value. This finding is in agreement with the finding that at any gestational age PIIINP levels are not correlated with body length. Similar conclusions were reached in studies on propeptide serum level and linear growth velocity in later childhood (2-5). Significantly lower propeptide values detected in nonmalformed SGA infants with a small OFC compared with age-matched SGA infants with normal head circumference suggest that the results of the PIIINP assay are related to the severity and duration of declining fetal growth. Interestingly, the multivariate analysis presented in our previous report on PIIINP assay (6) shows that, in addition to gestational age, head circumference has a significant independent positive correlation with the fetal PIIINP serum concentration. Small OFC in nonmalformed SGA infants-a well-recognized index of "chronic" nutritional deprivation-is thought to be induced, during longstanding uteroplacental insufficiency, by the collapse of the preferential brain perfusion (1). The latter hypothesis has received valuable support from the results of in vivo studies of Doppler flow in the internal carotid artery of growth-retarded human fetuses (14).
Not preeclampsia itself but rather the ensuing fetal growth deceleration is solely responsible for the decrease in fetal cord serum propeptide levels. It is hardly surprising that AGA infants of diabetic mothers have propeptide values similar to age-matched controls, because their often higher PI are mainly due to fat accumulation instead of higher accretion of protein (17). That serum PIIINP concentrations are independent of serum levels of IGF-I is in agreement with such a proposition (16).
The fact that maternal serum PIIINP values rise toward the end of a normal pregnancy and are still higher in a complicated pregnancy (e.g. multiple birth, preeclampsia) helps repudiate the assumption that transplacental transfer of propeptides would explain the higher PIIINP levels in premature infants (present data; 18).
Congenital anomalies seemed not to be associated with any alteration of propeptide concentration, provided they did not cause intrinsic fetal growth deceleration. However, the finding of extremely high cord serum levels of PIIINP in six newborn infants with various types of the Potter sequence of malformation prompts a separate discussion. It may be surmized that PIIINP accumulation occurs in the fetal circulation due to the absence of renal function and that normally large amounts of procollagen propeptides or their fragments may be excreted by the fetal kidneys into the amniotic fluid. However, Keller et al. (19) have demonstrated that, although serum PIIINP values (ABB and FAB assay) of adult kidney patients correlated directly (r, = 0.41, p = 0.001) with serum creatinine levels and were significantly higher than in the serum of healthy volunteers, PIIINP elimination did not depend on renal function. These authors assumed that increased intrarenal collagen production due to progressive renal fibrosis could explain the elevated PIIINP serum levels in all kidney patients. This hypothesis is obviously not applicable to our neonates with bilateral renal agenesis. The speculation that propeptides may be
